The Business Research Company’s Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON, UK, April 7, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The companies operating in the biosimilars industry are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche’s Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis.
The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA).
Read More On The Global Rituximab Biosimilars Market Report:
The rituximab biosimilar industry analysis report is segmented by application into non-hodgkin’s lymphoma, chronic lymhocytic leukemia, rheumatoid arthritis, others, by distribution channel into hospital pharmacy, online pharmacy, retail pharmacy, other direct distribution channels, and by route of administration into subcutaneous, intravenous, and molecular type.
The global rituximab biosimilars market is expected to grow from $1.75 billion in 2020 to $1.9 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The rituximab biosimilars market is expected to reach $3.02 billion in 2025 at a CAGR of 12%.
Major players in the rituximab (rituxan) treatment market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd.
Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market overview, forecast rituximab biosimilars market size and growth for the whole market, rituximab biosimilars market segments, and geographies, rituximab biosimilars market trends, rituximab biosimilars market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Rituximab Biosimilars Market Report:
Here Is A List Of Similar Reports By The Business Research Company:
Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
Blood Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030
Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293